Canadians living with mental health conditions stand to save over $57 billion with use of pharmacogenetic testing

NEXT STORY
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
PREV STORY
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC

MADISON, Wis., March 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), ...

author_avatar
NASDAQ Market News

GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers

GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers GENFIT significantly contributes ...

author_avatar
NASDAQ Market News

New Research Shows BiovaDerm(R) Reduces the Appearance of Wrinkles

JOHNSTON, IOWA, Nov. 7, 2016 (GLOBE NEWSWIRE) -- Topical use of BiovaDerm®, a water ...

author_avatar
NASDAQ Market News